CORRECTION Open Access

Correction: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment

C. Martínez-Laperche^{1,2}, L. Sanz-Villanueva^{1,2}, F. J. Díaz Crespo^{1,3}, P. Muñiz^{1,2}, R. Martín Rojas², D. Carbonell^{1,2}, M. Chicano^{1,2}, J. Suárez-González^{1,4}, J. Menárguez^{1,3}, M. Kwon^{1,2}, J. L. Diez Martín^{1,2,5}, I. Buño^{1,2,4,6} and M. Bastos Oreiro 1,2*

Correction: BMC Cancer 22, 982 (2022) https://doi.org/10.1186/s12885-022-10070-z

Following publication of the original article [1], the authors identified an error in Fig. 1B. Patients with EZH2 mutation (n=7) have worse prognosis than patients without mutation (n=23). The updated Fig. 1 is supplied in this correction article.

The original article [1] has been corrected.

Author details

¹Gregorio Maranon Health Research Institute (IiSGM), Madrid, Spain. ²Department of Hematology, Gregorio Marañón General University Hospital, Gregorio Marañón Health Research Institute (IiSGM), C/ Doctor Esuerdo 46, 28007 Madrid, Spain. ³Pathology Department, Gregorio Maranon General University Hospital, Madrid, Spain. ⁴Genomics Unit, Gregorio Maranon General University Hospital, IiSGM, Madrid, Spain. ⁵Department of Medicine, School of Medicine, Complutense University of Madrid, Madrid, Spain. ⁶Department of Cellular Biology, School of Medicine, Complutense University of Madrid, Madrid, Spain.

Published online: 28 November 2022

The original article can be found online at https://doi.org/10.1186/s12885-022-10070-7.

*Correspondence: marianabeatriz.bastos@salud.madrid.org

Full list of author information is available at the end of the article



Reference

Martínez-Laperche C, Sanz-Villanueva L, Díaz Crespo FJ, et al. EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. BMC Cancer. 2022;22:982. https://doi.org/10.1186/ s12885-022-10070-z.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

² Department of Hematology, Gregorio Marañón General University Hospital, Gregorio Marañón Health Research Institute (IiSGM), C/ Doctor Esuerdo 46, 28007 Madrid, Spain




Fig. 1 Kaplan-Meier curves in patients with grade 1, 2, and 3a. **A** PFS and OS in patients treated with R-CHOP (*EZH2* mutated vs. unmutated); **B** PFS and OS in patients treated with R-Bendamustine (*EZH2* mutated vs. unmutated). **C** PFS and OS in *EZH2* mutated patients (R-CHOP vs. R-Bendamustine). PFS Progression-free survival. OS: Overall survival